Interleukin-4 Antibodies: A Transformative Therapy Precisely Targeting the Core of Type 2 Immunity

I. What is Interleukin-4? Why is it so critical in the immune system?

Interleukin-4 (IL-4) is a pleiotropic cytokine primarily produced by activated type 2 helper T cells (Th2), mast cells, basophils, and type 2 innate lymphoid cells (ILC2s). It serves as the undisputed core commander and regulatory hub of type 2 immune responses. Its function extends far beyond simple signal transmission; rather, it fundamentally shapes the landscape and progression of immune responses by regulating gene expression. IL-4 exerts its biological effects by binding to its receptor complex, which primarily consists of two types: Type I receptors (composed of the IL-4Rα chain and the common γ-chain γc), mainly expressed on hematopoietic cells (e.g., lymphocytes), and Type II receptors (composed of the IL-4Rα chain and the IL-13Rα1 chain), more widely expressed on non-hematopoietic cells (e.g., epithelial cells, fibroblasts, smooth muscle cells). When IL-4 binds to its receptor, it initiates the intracellular JAK-STAT signaling pathway (primarily JAK1/JAK3/STAT6), acting like a genetic key to unlock a series of critical physiological and pathological processes.

The core functions of IL-4 are manifested at multiple levels. First, it is a decisive factor in Th2 cell differentiation. Naive CD4+ T cells, upon receiving IL-4 signals, preferentially differentiate into Th2 cells, creating a powerful positive feedback loop that amplifies type 2 immune responses. Second, it is the key switch for B cell class switching and IgE antibody production. B cells must receive signals from IL-4 (or IL-13) to switch from producing IgM to producing IgE—the core antibody in allergic reactions. Additionally, IL-4 upregulates the expression of vascular cell adhesion molecule-1 (VCAM-1), promoting the recruitment of inflammatory cells such as eosinophils to tissue sites; stimulates epithelial cells and fibroblasts, leading to excessive mucus secretion and goblet cell hyperplasia; and participates in alternative macrophage activation (M2 polarization), playing a role in allergies and fibrosis. Thus, IL-4 occupies a pivotal position, serving as both an "initiator" of type 2 immune responses and an "executor" of their downstream pathological effects, making it an ideal therapeutic target for related diseases.

II. How does IL-4 drive the pathological processes of allergic diseases?

The core driving role of IL-4 in allergic diseases can be likened to the leader of an "axis of evil," operating through multiple parallel and interconnected pathways that collectively contribute to the typical symptoms and chronic progression of these diseases. In the pathogenesis of allergic asthma, IL-4 plays multiple roles. After inhalation of allergens, antigen-presenting cells activate naive T cells. In the existing IL-4 microenvironment, these T cells differentiate into Th2 cells and produce more IL-4, forming an autocrine loop. This IL-4 directly acts on B cells, prompting them to produce large amounts of allergen-specific IgE antibodies. These IgE antibodies then bind to FcεRI receptors on the surface of mast cells and basophils, sensitizing the body. Upon re-exposure to the same allergen, these cells rapidly degranulate, releasing pre-stored mediators such as histamine and leukotrienes, causing acute bronchoconstriction, vasodilation, and mucus secretion—the hallmark of an acute asthma attack. Simultaneously, IL-4 directly acts on airway structural cells: it stimulates airway epithelial cells and goblet cells to produce excessive mucus, clogging already narrowed airways; it promotes the proliferation and enhanced contractility of airway smooth muscle cells, leading to airway hyperresponsiveness (AHR), where the airways overreact to non-specific stimuli (e.g., cold air, smoke); and it participates in airway wall remodeling, including subepithelial fibrosis and smooth muscle thickening, which form the structural basis for the chronicity and irreversible airflow limitation in asthma.

In atopic dermatitis (AD), IL-4 is also a key pathogenic factor. IL-4 levels are significantly elevated in the skin of AD patients. IL-4 directly disrupts skin barrier function by inhibiting the expression of critical keratinocyte differentiation proteins (e.g., filaggrin), making the skin drier and more permeable to allergens and irritants. It strongly drives itching, and scratching further damages the skin barrier, creating an "itch-scratch" vicious cycle. Additionally, IL-4 promotes the infiltration and activation of Th2 cells in the skin and stimulates the recruitment of eosinophils, collectively leading to chronic eczematous dermatitis, epidermal thickening, and lichenification. Similarly, in chronic rhinosinusitis with nasal polyps (CRSwNP), allergic rhinitis, food allergies, and eosinophilic esophagitis (EoE), IL-4-driven IgE production, eosinophilic inflammation, mucus secretion, and tissue remodeling are common core pathological features. Thus, inhibiting IL-4 signaling is regarded as a strategic intervention to fundamentally reverse the pathological state of various type 2 inflammatory diseases.

III. How do antibody drugs targeting the IL-4/IL-13 pathway work?

Given the significant functional overlap between IL-4 and IL-13 (they share the Type II receptor and STAT6 signaling pathway) and their synergistic role in driving diseases, the most successful therapeutic strategy has been to develop bispecific antibodies that simultaneously inhibit both cytokines or target their shared receptor chain. Dupilumab is a paradigm and breakthrough achievement of this strategy. Dupilumab is a fully human monoclonal antibody that does not directly bind to IL-4 or IL-13 but precisely targets their shared receptor subunit—IL-4Rα. IL-4Rα is an indispensable component of both functional Type I and Type II receptors. By binding with high affinity to IL-4Rα, dupilumab physically blocks the binding of IL-4 and IL-13 to their respective receptors, thereby simultaneously inhibiting signaling mediated by both cytokines.

This upstream receptor-level blockade produces profound and extensive downstream biological effects, akin to cutting multiple fuses at once. First, it significantly inhibits IL-4-driven Th2 cell differentiation and expansion, reducing the "production factory" of type 2 cytokines at the source. Second, it almost completely blocks IgE class switching and production, substantially reducing circulating and tissue IgE levels, thereby alleviating allergen-triggered acute reactions. Third, it effectively inhibits the recruitment and activation of eosinophils, as this process relies on the combined action of IL-4 and IL-13. Fourth, it directly acts on tissue cells, reducing excessive mucus secretion (goblet cell hyperplasia) and alleviating itching sensations. Finally, evidence suggests that long-term use may help delay or even partially reverse pathological tissue remodeling. This multi-pronged mechanism of action enables dupilumab to produce profound and lasting therapeutic effects on a wide range of type 2 inflammation-driven diseases, achieving the strategic goal of "killing multiple birds with one stone."

IV. What is the clinical efficacy and impact of IL-4 antibodies (e.g., dupilumab)?

The clinical development of dupilumab is a tremendous success story in translational immunology. Its efficacy has been repeatedly validated in multiple large-scale, randomized, double-blind, placebo-controlled Phase III clinical trials, and it has fundamentally transformed the treatment landscape for many diseases. In the treatment of moderate-to-severe atopic dermatitis, dupilumab has demonstrated revolutionary effects. Compared to traditional topical corticosteroids and immunosuppressants, dupilumab significantly improves patients' Eczema Area and Severity Index (EASI), Pruritus Numerical Rating Scale (NRS) scores, and greatly enhances their quality of life. Its rapid onset, relatively high safety profile, and lack of need for routine laboratory monitoring have quickly made it a cornerstone of systemic therapy for moderate-to-severe AD.

In the field of moderate-to-severe asthma, dupilumab provides a precise solution for uncontrolled patients with a type 2 inflammatory phenotype (evidenced by elevated blood eosinophils or FeNO levels). Clinical trials have shown that it reduces asthma exacerbation rates by nearly 50%, improves lung function (FEV1), reduces the use of rescue medications, and allows patients to reduce or even discontinue oral corticosteroids, thereby avoiding the severe side effects associated with long-term steroid use. Similarly, in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), dupilumab significantly reduces nasal polyp size, improves nasal congestion, restores the sense of smell, and reduces the need for repeat surgeries. Additionally, it has shown remarkable efficacy in eosinophilic esophagitis (EoE), prurigo nodularis, and other indications, with ongoing exploration for various other Th2 inflammation-mediated diseases. The success of dupilumab not only validates the effectiveness of precisely targeting the IL-4/IL-13 pathway but also pioneers a new paradigm of "one drug treating multiple diseases," offering unprecedented hope to countless patients.

V. What are the current challenges and future directions?

Despite the remarkable achievements of therapies targeting the IL-4 pathway, challenges and future directions remain clear. The primary challenge is primary or secondary drug resistance. Not all patients respond adequately to treatment, possibly due to alternative activation or dominance of other inflammatory pathways (e.g., IL-5, IL-31, IL-22, IL-23/Th17 axis). This leads to the first future direction: combination therapy and precise phenotyping. Future clinical practice will increasingly rely on biomarkers (e.g., blood eosinophils, FeNO, IgE, specific cytokine profiles) to finely phenotype patients, determining whether they are purely IL-4/IL-13-driven, mixed-type, or non-type 2. For mixed-type cases, combining IL-4/IL-13 inhibitors with inhibitors of other pathways (e.g., IL-5, IL-23) may be key to tackling refractory cases.

Second, long-term safety requires ongoing monitoring. Although dupilumab's safety profile is generally favorable, the long-term effects of systemic immune suppression, particularly on defenses against parasitic infections and responses to vaccination, need more real-world data. Third, optimizing the route and frequency of administration is crucial for improving patient adherence and quality of life. While the current subcutaneous injection every two or four weeks is a significant advancement, longer-acting formulations (e.g., every six months) or oral small-molecule inhibitors (e.g., JAK inhibitors or STAT6 inhibitors under development) may be future competitive directions. Fourth, the continued expansion of indications is underway. From allergic diseases to fibrotic diseases (e.g., idiopathic pulmonary fibrosis), certain neurological disorders, and even oncology, the potential role of IL-4 is continually being explored, opening broader application prospects for such therapies. Finally, accessibility and cost remain significant challenges globally, requiring concerted efforts from governments, payers, and companies to ensure this transformative therapy reaches more patients.

In conclusion, IL-4 antibodies, particularly the receptor-blocking strategy exemplified by dupilumab, mark our entry into a new era of precision immunotherapy. It is not merely a drug but a powerful research tool and clinical paradigm. It validates that discoveries in basic immunology can be translated into disruptive medical interventions, profoundly changing our understanding, classification, and treatment of complex immune diseases. Its impact will be far-reaching and enduring.

Click on the product catalog numbers below to access detailed information on our official website.

Product Information